<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808988</url>
  </required_header>
  <id_info>
    <org_study_id>OMÜ KAEK 2012/138</org_study_id>
    <nct_id>NCT02808988</nct_id>
  </id_info>
  <brief_title>Changes of GCF Levels of RANKL and Osteoprotegerin in Postmenopausal Osteoporosis</brief_title>
  <official_title>Effect of Periodontal Therapy and Bisphosphonates on Gingival Crevicular Fluid Levels of Nuclear Factor- κb Ligand (RANKL) and Osteoprotegerin in Postmenopausal Osteoporosis: Results of a 12-Month Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ondokuz Mayıs University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ondokuz Mayıs University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators evaluated the effect of initial periodontal treatment on clinical findings
      and receptor activator of Nuclear Factor-kappa B ligand (RANKL) and osteoprotegerin (OPG) in
      gingival crevicular fluid (GCF) of patients with osteoporosis under bisphosphonate therapy
      within 12 months' follow-up. Clinical recordings and GCF were obtained from postmenopausal
      women; with chronic periodontitis and osteoporosis (Group A, n=13), with chronic
      periodontitis and no osteoporosis (Group B, n=12), without chronic periodontitis and
      osteoporosis (Group C, n=12), systemically and periodontally healthy controls (Group D, n=10)
      at the baseline. Recordings were repeated at the 1st, 6th and 12th months in Group A, B and
      C. RANKL and OPG values were measured by enzyme-linked immunosorbent assays.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study groups were selected from postmenopausal patients those referred to Department of
      Endocrinology, School of Medicine, Ondokuz Mayis University. Bone mineral density (BMD)
      measurements were performed by dual energy-X-ray absorptiometry from L1-L4 site of lumbar
      vertebra and/or femur (g/cm2). Osteoporosis was defined as T scores less than -2.5 at L1-L4,
      femur neck or total femur. Women with T scores less than -2.5 (groups A and C) were started
      on bisphosphonate treatment after their initial periodontal examination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gingival crevicular fluid levels of osteoprotegerin (OPG) and receptor activator of Nuclear Factor-kappa B ligand (RANKL)</measure>
    <time_frame>Changes from Baseline osteoprotegerin (OPG) and receptor activator of Nuclear Factor-kappa B ligand (RANKL) at 12 months</time_frame>
    <description>molecules having roles in bone resorption</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Chronic Periodontitis</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>periodontal phase 1 therapy consisted of scaling and root planning, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>periodontal phase 1 therapy consisted of scaling and root planning, no bisphosphonate therapy,gingival crevicular fluid collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no periodontal phase 1 therapy, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no periodontal phase 1 therapy, no bisphosphonate therapy,gingival crevicular fluid collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>periodontal phase 1 therapy</intervention_name>
    <description>periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia and gingival crevicular fluid collection by the same investigator.</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>gingival crevicular fluid collection</intervention_name>
    <description>gingival crevicular fluid collection by periopapers</description>
    <arm_group_label>group C</arm_group_label>
    <arm_group_label>group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>5 mg/year zoledronic acid (i.v.)</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with T scores less than -2.5 (groups A and C)

          -  The periodontitis patients were selected based on the radiographical evidence of bone
             loss, presence of four or more sites with bleeding on probing (BOP), ≥5 mm pocket
             depth (PD) and ≥6 mm clinical attachment loss (CAL).

          -  The clinically healthy control groups were selected on the basis of no radiographic
             bone loss or CAL and PD≤3 mm.

        Exclusion Criteria:

          -  Any known systemic disease rather than osteoporosis

          -  Smoking

          -  Antibiotic therapy within the last 3 months

          -  Periodontal treatment within the last 6 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eser Sakallıoğlu, PhD,Prof.Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Ondokuz Mayıs University, School of Dentistry, Department of Periodontology, Samsun, Turkey</affiliation>
  </overall_official>
  <reference>
    <citation>Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Horm Metab Res. 2008 Apr;40(4):281-5. doi: 10.1055/s-2008-1046787. Epub 2008 Feb 15.</citation>
    <PMID>18275008</PMID>
  </reference>
  <results_reference>
    <citation>Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang HY, Jeffcoat M, Munoz T. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol. 2005 Jul;76(7):1113-22.</citation>
    <PMID>16018754</PMID>
  </results_reference>
  <results_reference>
    <citation>Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res. 2004 Feb;83(2):166-9.</citation>
    <PMID>14742657</PMID>
  </results_reference>
  <results_reference>
    <citation>Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, Töz H, Atilla G, Hughes FJ, Belibasakis GN. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol. 2007 May;34(5):370-6. Epub 2007 Mar 13.</citation>
    <PMID>17355365</PMID>
  </results_reference>
  <results_reference>
    <citation>Babür C, Ozcan G, Cebi DU, Pervane B, Ozdemir B, Yücel A, Biri AA, Babür C. Gingival crevicular fluid levels of osteoprotegerin (OPG) in premenopausal and postmenopausal women with or without chronic periodontitis. J Dent. 2012 May;40(5):364-71. doi: 10.1016/j.jdent.2012.01.013. Epub 2012 Feb 2.</citation>
    <PMID>22326720</PMID>
  </results_reference>
  <results_reference>
    <citation>Gümüş P, Buduneli E, Bıyıkoğlu B, Aksu K, Saraç F, Nile C, Lappin D, Buduneli N. Gingival crevicular fluid, serum levels of receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-17 in patients with rheumatoid arthritis and osteoporosis and with periodontal disease. J Periodontol. 2013 Nov;84(11):1627-37. doi: 10.1902/jop.2013.120595. Epub 2013 Jan 17.</citation>
    <PMID>23327689</PMID>
  </results_reference>
  <results_reference>
    <citation>Bostanci N, Saygan B, Emingil G, Atilla G, Belibasakis GN. Effect of periodontal treatment on receptor activator of NF-κB ligand and osteoprotegerin levels and relative ratio in gingival crevicular fluid. J Clin Periodontol. 2011 May;38(5):428-33. doi: 10.1111/j.1600-051X.2011.01701.x. Epub 2011 Jan 24.</citation>
    <PMID>21261673</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>June 19, 2016</last_update_submitted>
  <last_update_submitted_qc>June 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ondokuz Mayıs University</investigator_affiliation>
    <investigator_full_name>Feyza Otan ÖZDEN</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Bisphosphonate</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>RANKL</keyword>
  <keyword>OPG</keyword>
  <keyword>periodontitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

